Ken Fisher Catalyst Pharmaceuticals, Inc. Transaction History

Fisher Asset Management, LLC

$243 Billion
Q3 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 86,797 shares of CPRX stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,797

Previous 105,535 17.76%

Holding current value

$1.85 Million

Previous $1.63 Million 5.57%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$15.19 - $21.35 $284,630 - $400,056	-18,738 Reduced 17.76%	86,797 $1.73 Million
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $103,993 - $119,861	-7,084 Reduced 6.29%	105,535 $1.63 Million
Q1 2024 May 09, 2024	BUY	$13.18 - $17.11 $12,586 - $16,340	955 Added 0.86%	112,619 $1.8 Million
Q2 2023 Aug 08, 2023	SELL	$11.5 - $18.08 $1,150 - $1,807	-100 Reduced 0.09%	111,664 $1.5 Million
Q1 2023 May 01, 2023	SELL	$14.34 - $21.05 $312,669 - $458,974	-21,804 Reduced 16.32%	111,764 $1.85 Million
Q4 2022 Feb 03, 2023	SELL	$12.25 - $19.5 $1.93 Million - $3.07 Million	-157,329 Reduced 54.08%	133,568 $2.48 Million
Q2 2022 Aug 09, 2022	BUY	$6.23 - $8.57 $189,572 - $260,776	30,429 Added 11.68%	290,897 $2.04 Million
Q1 2022 May 05, 2022	SELL	$5.31 - $8.31 $26,996 - $42,248	-5,084 Reduced 1.91%	260,468 $2.16 Million
Q4 2021 Feb 02, 2022	BUY	$5.21 - $7.45 $332,142 - $474,944	63,751 Added 31.59%	265,552 $1.8 Million
Q3 2021 Oct 26, 2021	BUY	$4.85 - $6.04 $978,734 - $1.22 Million	201,801 New	201,801 $1.07 Million

Others Institutions Holding CPRX

# of Institutions

326

Shares Held

94M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.19B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account